Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Patient Trial Of Personalized Two-Drug Therapy For Brain Tumors Launched

Avastin and Tarceva, which target different tumor-growth pathways, are being studied by the Brain Tumor Trials Collaborative, which includes 13 centers across the nation.

Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Cedars-Sinai Medical Center that combines two innovative drugs.

Cedars-Sinai’s Cochran Brain Tumor Center is the only site in California and one of only 13 in the nation offering this experimental therapy through the Brain Tumor Trials Collaborative (BTTC) based at M.D. Anderson Cancer Center in Houston.

Glioblastoma multiforme is a highly aggressive, treatment-resistant brain tumor. Even with standard therapies – surgery, chemotherapy and radiation – patient survival averages less than 15 months.

The two anticancer drugs, Avastin® (bevacizumab) and Tarceva® (erlotinib), work through different molecular mechanisms to attack brain tumors. Avastin inhibits vascular endothelial growth factor (VEGF), a protein that contributes to the formation of blood vessels that tumors need for growth. Tarceva is designed to prevent tumor growth by blocking a signal pathway that controls cell division by binding to a cancer cell membrane receptor called epidermal growth factor (EGFR).

Although single-agent targeted therapies have not produced significant improvements in treating glioblastomas, laboratory experiments and studies in animals suggest that a combination approach may have greater impact. This two-drug combination is also in clinical trials for the treatment of other cancers, including non-small cell lung cancer and renal cell carcinoma.

While all glioblastoma multiforme tumors share certain characteristics, they are not all genetically alike. This patient trial is specifically designed for those whose tumor cells have “unmethylated MGMT promoter.” This provides an especially strong study of the effects of the new two-drug approach because these tumors are resistant to the type of chemotherapy typically prescribed for patients with glioblastoma.

“Unmethylated MGMT promoter” means that a gene involved in repairing damaged tumor DNA is highly active in the tumor cells. When this gene, MGMT (O6-methylguanine-DNA methyltransferase), is functioning in cancer cells, it makes the tumor resistant to certain types of chemotherapy – including temozolamide, which is often used to treat glioblastoma – because it helps repair the damage the drug inflicts. On the other hand, if the gene is “silenced” (blocked) – through a process called methylation – the tumor will be more vulnerable to temozolomide.

The two-drug therapy will be administered after standard treatment with temozolomide and radiation therapy. Because radiation has been found to increase activation of certain molecular factors that the two drugs target, it is theorized that radiation therapy may stimulate a greater antitumor effect from the drugs.

Additional information on the clinical trial is available by calling 310-423-3062 or by visiting:

The mission of the Brain Tumor Trials Collaborative “is to develop and perform hypothesis-based, state-of-the-art clinical trials in a collaborative and collegial environment, emphasizing innovation and meticulous attention to protocol compliance and date quality.” The group is led by researchers at M.D. Anderson Cancer Center in Houston and includes investigators at Cedars-Sinai and 11 other cancer research and treatment centers across the nation.

Other current members are: Baylor University Medical Center, Dallas; Dana Farber Cancer Center, Boston, M.D. Anderson Cancer Center – Orlando, Fla.; Medical University of South Carolina, Charleston; Memorial Sloan-Kettering Cancer Center, N.Y.; Methodist Hospital System, Houston; Northshore University Health System, Chicago; Northwestern University Feinberg School of Medicine, Chicago; Ohio State University A.G. James Cancer Hospital, Columbus; the University of Washington, Seattle; and the University of Texas Southwestern in Dallas.

Sandy Van | Cedars-Sinai News
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

Im Focus: Radar for navigation support from autonomous flying drones

At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.

Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

International Virtual Reality Conference “IEEE VR 2018” comes to Reutlingen, Germany

08.03.2018 | Event News

Latest News

Wandering greenhouse gas

16.03.2018 | Earth Sciences

'Frequency combs' ID chemicals within the mid-infrared spectral region

16.03.2018 | Physics and Astronomy

Biologists unravel another mystery of what makes DNA go 'loopy'

16.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>